Vericel Corp
VCEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000887359
In the last 90 days, Vericel Corp insiders filed 0 open-market purchases and 3 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.47B in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Vericel Corp as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 320
- +43 vs. Q1 2026
- Shares held
- 55.6M
- +167.8K (+0.3%) vs. Q1 2026
- Total value
- $2.47B
- +$690.0M (+38.7%) vs. Q1 2026
- New holders
- 65
- 121 more added
- Sold out
- 22
- 100 more reduced
3 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VCEL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 320 | $2.47B |
| Q1 2026 | 280 | $1.78B |
| Q4 2025 | 274 | $1.93B |
| Q3 2025 | 249 | $1.67B |
| Q2 2025 | 273 | $2.35B |
| Q1 2025 | 277 | $2.39B |
| Q4 2024 | 278 | $2.87B |
| Q3 2024 | 268 | $2.15B |
| Q2 2024 | 261 | $2.32B |
| Q1 2024 | 257 | $2.68B |
| Q4 2023 | 227 | $1.84B |
| Q3 2023 | 214 | $1.73B |
| Q2 2023 | 202 | $1.88B |
| Q1 2023 | 200 | $1.48B |
| Q4 2022 | 178 | $1.32B |
| Q3 2022 | 180 | $1.21B |
| Q2 2022 | 183 | $1.34B |
| Q1 2022 | 197 | $2.01B |
| Q4 2021 | 185 | $2.04B |
| Q3 2021 | 202 | $2.48B |
| Q2 2021 | 205 | $2.57B |
| Q1 2021 | 205 | $2.75B |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Vericel Corp; share changes are against Q1 2026.